DAC
BMS Data Sharing Request Committee
| Dac ID | Contact Person | Access Information | |
|---|---|---|---|
| EGAC00001001667 | CTT Group | ctt [dot] group [at] bms [dot] com | No additional information is available |
This DAC controls 1 dataset:
| Dataset ID | Description | Technology | Samples |
|---|---|---|---|
| EGAD00001006284 | We analyzed baseline and on-therapy tumor biopsies from 101 patients with advanced melanoma treated with nivolumab (anti-PD-1) alone or combined with ipilimumab (anti-CTLA-4). Analysis of whole transcriptome data showed that T cell infiltration and interferon-gamma signaling signatures corresponded most highly with clinical response to therapy, with a reciprocal decrease in cell cycle and WNT signaling pathways in responding biopsies. Clinical outcome differences were likely not due to differential melanoma cell responses to interferon-gamma, as 57 human melanoma cell lines exposed in vitro to this cytokine showed a conserved interferon-gamma transcriptome response unless they had mutations that precluded signaling from the interferon-gamma receptor. Therefore, the magnitude of the antitumor T cell response and the corresponding downstream interferon-gamma signaling are the main drivers of clinical response or resistance to immune checkpoint blockade therapy. | Illumina HiSeq 2000 | 70 |
